Alnylam Pharmaceuticals Hits 52-Week Low at USD 281.68

Alnylam Pharmaceuticals, Inc. has reached a significant milestone by touching a new 52-week low of USD 281.68 on June 15, 2026. This marks a notable decline from its previous high of USD 495.31, reflecting the stock's recent volatility within the pharmaceuticals and biotechnology sector. Despite this downturn, Alnylam Pharmaceuticals has demonstrated a strong one-year performance, boasting an impressive increase of 87.53%, significantly outpacing the S&P 500's performance of 26.39%. The company's market capitalization stands at USD 42,089 million, categorizing it as a mid-cap entity. Financial metrics reveal a price-to-earnings (P/E) ratio of 118.00, indicating a premium valuation relative to earnings. The company maintains a return on equity of 45.14%, showcasing its efficiency in generating profits from shareholders' equity. Additionally, Alnylam Pharmaceuticals has a price-to-book ratio of 53.33, reflecting its market valuation compared to its book value. As the company navigates through this period, its financial indicators will be closely monitored for any shifts in market dynamics.